Fragile X syndrome
Nov 08, 2022
Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma
Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...
Read More...
Dec 13, 2019
Fragile X Syndrome Market
AI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in R&D related to rare neurological disorders. Under the deal signed, Healx Artificial Intelligence (AI) drug discovery platfo...
Read More...
Dec 21, 2018
Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal
Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equ...
Read More...
Jan 20, 2017
Fragile X syndrome: X-linked mental retardation and macroorchidism
Fragile X syndrome (FXS) is an inherited genetic condition that causes mental retardation, intellectual disability, and autism. Etiology of the disease includes the defect in the FMR1 gene located on the X-chromosome, which prevents the gene from properly synthesising a protein called the fragile X mental retardatio...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
